Following the integration, Frenova, a contract clinical renal research service provider and former subsidiary of Fresenius, will now offer its clinical development services worldwide through Fresenius’ recently opened global medical office.
Previously, Frenova provided clinical development for kidney targeted therapeutics to companies only within North America. With its collaboration with Fresenius, Frenova’s offerings will now be bundled with the corresponding services of the former’s Europe, Middle East and Africa, and Latin America regions.
The global medical office will be led by Frank Maddux, chief medical officer at Fresenius.
Maddux said in a statement, “Frenova is active at the intersection of clinical research and patient care. By making this expertise available worldwide, we will enable a faster more efficient development of medications and other products. This is an additional, important building block for improving their [patients] quality of life.”
Frenova recently expanded its site network in an aim to accelerate clinical trial enrollment. The company added an additional location, the Nevada Kidney Disease and Hypertension Centers in Las Vegas, to its managed clinical research sites. Frenova’s own network now includes more than 450 principal investigators across over 260 sites.
When bundled Fresenius’ and Frenova’s research efforts will be able to reach more than 550 researchers in over 350 locations.
